Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.31 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.31 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.31 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9971203 | 0.81 | MAPK1 (0.34) | L3MBTL1MAPTLGALS8LGALS3LGALS4 | |
| SCHEMBL15304344 | 0.81 | MAPK1 (0.34) | L3MBTL1MAPTLGALS8LGALS3LGALS4 | |
| SCHEMBL14536556 | 0.81 | MAPK1 (0.34) | L3MBTL1MAPTLGALS8LGALS3LGALS4 | |
| SCHEMBL25597683 | 0.78 | GJB2 (0.38) | LGALS8LGALS3LGALS4 | |
| SCHEMBL13241371 | 0.77 | LGALS8 (0.31) | L3MBTL1LGALS8LGALS3LGALS4 | |
| SCHEMBL9968286 | 0.77 | LGALS8 (0.31) | L3MBTL1LGALS8LGALS3LGALS4 | |
| SCHEMBL14959353 | 0.74 | L3MBTL1 (0.30) | L3MBTL1 | |
| SCHEMBL14959352 | 0.73 | ACHE (0.31) | — | |
| SCHEMBL18902390 | 0.73 | L3MBTL1 (0.35) | L3MBTL1MAPTLGALS8SYNJ2 | |
| SCHEMBL23591465 | 0.72 | L3MBTL1 (0.57) | L3MBTL1MAPTLGALS8LGALS3LGALS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | AGILENT TECHNOLOGIES, INC. | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100136-A1 | Monomer compositions for the synthesis of RNA, methods of synthesis, and methods of deprotection | RNGTT, RNMT, NSUN2 | L3MBTL1 474/4885MAPT 2498/4885LGALS8 2122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.